The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Maintenance nivolumab in post-stem cell transplant Hodgkin lymphoma
Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discusses data from the single-arm Phase II trial (NCT03436862) of nivolumab, an anti-PD-1 monoclonal antibody, as maintenance therapy in patients with Hodgkin lymphoma who have undergone autologous stem cell transplant. Maintenance brentuximab vedotin is currently the standard of care and 37 patients were enrolled in the trial to receive nivolumab. Whilst some patients discontinued treatment due to adverse events, progression-free survival was 92.1% and overall survival was 100% after a 9 month follow-up. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
